The inhibition of the PD-1/PD-L1 pathway enhances antitumor immunity to prevent tumor cells from escaping from host immune responses, thus providing a promising strategy for specific tumor immunotherapy [21]. The gene discussed is PDCD1; the disease is neoplasm.